NFKB1 and diffuse large B-cell lymphoma: Nuclear factor kB (NF-kB) activation is often enhanced in the inflammatory DLBCL subgroup with PD-L1 SVs (Godfrey et al., 2019), however, the combination of pembrolizumab plus lenalidomide did not exhibit an obvious synergistic effect, the ORR in KEYNOTE-013 study was similar to that of lenalidomide monotherapy in ReMIND study (39% vs. 34%) (Zinzani et al., 2021).